Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Jazz Pharmaceuticals PLC(JAZZ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for JAZZ
10/06/2026: JAZZ (5-star) is currently NOT-A-BUY. Pass it for now.
Jazz Pharmaceuticals is a mid-sized biopharmaceutical company focusing on high-unmet-need areas in neuroscience and oncology. Its main strengths include a specialized, high-margin portfolio with key products like Xywav and Epidiolex, and a consistent history of using M&A to grow its pipeline. The primary growth opportunity lies in label expansions for existing therapies and successful advancement of its oncology candidates. Risks include significant revenue concentration in legacy products, potential patent litigation, and the burden of debt incurred from acquisitions. It is generally best suited for growth-oriented investors who can tolerate the volatility associated with drug development, clinical trial outcomes, and ongoing M&A-driven strategy.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company relies on clinical trial results and product launches, which provide growth but carry significant execution risk. |
| Momentum investor | Strong fit while signal remains positive | Jazz can experience sharp price movements based on regulatory announcements or M&A developments. |
| Value investor | Mixed fit | Valuation is often tied to the patent cliff of its legacy drugs, making long-term value assessment complex. |
| Dividend investor | Weak fit | The company does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Clinical trial outcomes and regulatory hurdles introduce higher volatility than typical for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical, regulatory, and patent news. |
| Valuation risk | Medium / high | Future growth expectations are highly dependent on the success of new product launches. |
| Competition risk (Generic and Novel entrants) | Medium / high | The sleep disorder market is seeing increased competition which threatens long-term margins. |
| Business quality | Medium | The company has a solid commercial engine but is reliant on M&A to sustain its portfolio pipeline. |
| Dividend income | Low / none | The company currently reinvests all cash into growth, providing no yield. |
| Execution risk | Medium | Integrating acquisitions and managing complex product lifecycles is essential for long-term viability. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 73.73% | Avg. Invested days 70 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.32B USD | Price to earnings Ratio 16.14 | 1Y Target Price 294.27 |
Price to earnings Ratio 16.14 | 1Y Target Price 294.27 | ||
Volume (30-day avg) 1.0M shares | Beta 0.37 | 52 Weeks Range 128.80 - 266.38 | Updated Date 10/06/2026 |
52 Weeks Range 128.80 - 266.38 | Updated Date 10/06/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 14.62 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Neuroscience | Includes sales of Xywav, Xyrem, and related therapies for sleep disorders and epilepsy. | This is the core business; its success depends on maintaining patient access and defending against generic competition. |
| Oncology | Includes sales of Rylaze, Vyxeos, and Defitelio for hematologic cancers. | This segment provides diversification away from sleep disorders through specialized cancer treatments. |
| Geography (International) | Sales outside the United States, including European markets. | International expansion provides an additional, albeit smaller, revenue stream outside the US regulatory and pricing environment. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 16.14 | Forward PE 10.89 | Enterprise Value 17.47B | Price to Sales(TTM) 3.33 |
Enterprise Value 17.47B | Price to Sales(TTM) 3.33 | ||
Enterprise Value to Revenue 3.88 | Enterprise Value to EBITDA 11.03 | Shares Outstanding 64.91M | Shares Floating 62.98M |
Shares Outstanding 64.91M | Shares Floating 62.98M | ||
Percent Insiders 2.92 | Percent Institutions 102.37 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Jazz Pharmaceuticals PLC
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2007-06-01 | President, CEO & Director Ms. Renee D. Gala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2890 | Website https://www.jazzpharma.com |
Full time employees 2890 | Website https://www.jazzpharma.com | ||
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.